New FDA Approval: Osimertinib (TAGRISSO®) Combined with Chemotherapy for Treating EGFR-Mutated NSCLC
Learn about the FDA’s recent approval of the cancer treatment drug osimertinib, marketed as Tagrisso. Experience the latest breakthrough in non-small cell lung cancer treatment with osimertinib in combination with chemotherapy. View this @youtube video for more information.